Page last updated: 2024-09-05

24-norursodeoxycholic acid and Non-alcoholic Fatty Liver Disease

24-norursodeoxycholic acid has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boettler, T; Demir, M; Fickert, P; Geier, A; Greinwald, R; Halilbasic, E; Hofmann, WP; Kluwe, J; Kremer, AE; Manns, MP; Petersen, J; Pröls, M; Rainer, F; Schattenberg, JM; Spreda, F; Teuber, G; Trauner, M; Traussnigg, S; Wiegand, J	1
He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY	1

Reviews

1 review(s) available for 24-norursodeoxycholic acid and Non-alcoholic Fatty Liver Disease

Article	Year
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World journal of gastroenterology, 2016, Dec-28, Volume: 22, Issue:48 Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases	2016

Article

Year

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.

World journal of gastroenterology, 2016, Dec-28, Volume: 22, Issue:48

Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases

2016

Trials

1 trial(s) available for 24-norursodeoxycholic acid and Non-alcoholic Fatty Liver Disease

Article	Year
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:10 Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholagogues and Choleretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid	2019

Article

Year

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:10

Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholagogues and Choleretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid

2019